Despite downgrades, analysts still expect near tripling of Valeant's share price
Subscribe to Globe Unlimited now and get up-to-the minute insights on developing market news with Inside the Market! Valeant Pharmaceuticals International Inc. left even its most supportive analysts with a sense of unease after a conference call this week to review reduced profit targets. "How do we get comfortable that Valeant is able to execute and deliver for shareholders?" Shibani Malhotra, analyst with Nomura Securities, asked chief executive Michael Pearson on the call Tuesday.
from Biotech News